Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 9.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -326.53M |
| Shares Out | 27.88M |
| EPS (ttm) | -13.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,057,400 |
| Open | 326.08 |
| Previous Close | 327.86 |
| Day's Range | 314.00 - 334.27 |
| 52-Week Range | 37.19 - 366.52 |
| Beta | 2.75 |
| Analysts | Buy |
| Price Target | 617.67 (+88.44%) |
| Earnings Date | Aug 3, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in N... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for PRAX stock is "Buy." The 12-month stock price target is $617.67, which is an increase of 88.44% from the latest price.
News
Praxis Precision granted breakthrough therapy designation for elsunersen
Praxis Precision (PRAX) announced that the FDA has granted BTD for elsunersen, an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopat...
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizur...
Praxis Precision initiated with an Outperform at RBC Capital
RBC Capital analyst Leonid Timashev initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $449 price target The firm believes think ulixacaltamide has a “reasonable likelihood” o...
Praxis Precision Medicines Transcript: AGM 2026
The meeting introduced board members and officers, confirmed a quorum, and presented three proposals: director elections, auditor ratification, and advisory executive compensation approval. All proposals passed with majority or plurality support.
Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Essential tremor represents a large, underserved market, with ulixacaltamide positioned for a major launch and strong physician interest. The drug shows robust efficacy and safety, with commercial readiness and pricing strategies in place. Relutrigine and vormatrigine add to a promising pipeline.
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...
Praxis Precision falls -15.4%
Praxis Precision (PRAX) is down -15.4%, or -$51.69 to $283.47.
Praxis Precision price target lowered to $616 from $715 at Truist
Truist lowered the firm’s price target on Praxis Precision (PRAX) to $616 from $715 and keeps a Buy rating on the shares. The firm is citing the company announcement that…
Praxis Precision price target lowered to $650 from $750 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm’s price target on Praxis Precision (PRAX) to $650 from $750 and keeps an Outperform rating on the shares. The firm sees Monday’s announcement…
Praxis Precision price target lowered to $162 from $166 at Wedbush
Wedbush lowered the firm’s price target on Praxis Precision (PRAX) to $162 from $166 and keeps an Underperform rating on the shares. The firm notes the company reported the Phase…
Praxis Precision price target lowered to $810 from $843 at BTIG
BTIG lowered the firm’s price target on Praxis Precision (PRAX) to $810 from $843 and keeps a Buy rating on the shares. The company’s reported a topline miss on the…
Praxis Precision price target lowered to $400 from $433 at Baird
Baird lowered the firm’s price target on Praxis Precision (PRAX) to $400 from $433 and keeps an Outperform rating on the shares. The firm updated its model folowing news its…
Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Praxis Precision (PRAX) to $1,201 from $1,245 and keeps a Buy rating on the shares after the company announced the POWER1 trial…
Praxis Precision price target lowered to $374 from $420 at Deutsche Bank
Deutsche Bank analyst David Hoang lowered the firm’s price target on Praxis Precision (PRAX) to $374 from $420 and keeps a Buy rating on the shares. The company reported a…
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the main goal of a mid- to late-stage study, prompting it to pause enrollment in another ongoing study while i...
Praxis Precision Medicines trading resumes
16:45 EDT Praxis Precision (PRAX) Medicines trading resumes
Praxis Precision down 15% below $286 following POWER1 study update
16:47 EDT Praxis Precision (PRAX) down 15% below $286 following POWER1 study update
Praxis Precision reports POWER1 study misses endpoint, pauses POWER2 enrollment
Praxis Precision (PRAX) announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures, or FOS. “While the results for POWER1 were not what we…
Praxis Precision Medicines Provides Vormatrigine Program Update
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second ...
Praxis Precision Medicines trading halted, news pending
16:10 EDT Praxis Precision (PRAX) Medicines trading halted, news pending
Praxis Precision assumed with a Buy at Truist
Truist assumed coverage of Praxis Precision (PRAX) with a Buy rating and a price target of $715, up from $700. The company appears well positioned ahead of multiple value-inflecting catalysts…
Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026
The company is expanding its diversified royalty portfolio through acquisitions and disciplined investments, targeting 20% annual growth and robust cash flow. With a lean team and strong financials, it focuses on high-value, late-stage assets and leverages deep diligence to manage risk and drive compounding returns.
Praxis Precision price target lowered to $420 from $444 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Praxis Precision (PRAX) to $420 from $444 and keeps a Buy rating on the shares.
Praxis Precision price target raised to $166 from $130 at Wedbush
Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $166 from $130 and keeps an Underperform rating on the shares following quarterly results. The firm continues to hold…